The use of MDRD-eGFR to diagnose Chronic Kidney Disease (CKD) is based on the assumption that the algorithm will minimize the influence of age, gender and ethnicity that is observed in S-Creatinine concentration and thus allow a single cut-off at which further diagnostic and therapeutic actions should be considered. This hypothesis is tested in a retrospective analysis of outpatients (N=93,404) and hospitalised (N=35,572) patients in UK and Sweden, respectively. An algorithm based on the same model as the MDRD-eGFR algorithm was derived from simultaneously measured S-Creatinine concentrations and Iohexol GFR in a subset of 565 patients. The combined uncertainty of using this algorithm was estimated to about 15 % which is about three times that of the S-Creatinine concentration results. The diagnostic performance of S-Creatinine concentration was evaluated using the Iohexol clearance as the reference procedure. It was shown that the diagnostic capacity of MDRD-eGFR, as it stands, has no added value compared to S-Creatinine. The gender and age differences of the S-Creatinine concentrations in the dataset persist after applying the MDRD-eGFR algorithm. Thus, a general use of the MDRD-eGFR does not seem justified. Furthermore the claim that the eGFR is adjusted for body area is misleading; the algorithm does not include any body size marker. It is thus a dangerous marker for guiding drug administration.
SummaryHashimoto’s encephalopathy (HE) is rarely reported with only a few hundred cases published. Diagnosis is made in patients with an appropriate clinical picture and high antithyroperoxidase (anti-TPO) antibodies after infectious, toxic and metabolic causes of encephalopathy have been excluded. There is little objective data on the neurocognitive impairment in patients with HE and their improvement with treatment. We present the case of a 28-year-old woman with HE. Approach to management was novel as objective neuropsychological assessment was used to assess her clinical condition and response to treatment. Intravenous immunoglobulin (IVIg) as the first-line treatment instead of steroids. She responded well. The case illustrates that a different approach is required for the diagnosis and treatment of HE. A new diagnostic criteria is proposed that includes neurocognitive assessment, serum and CSF antibodies, an abnormal EEG and exclusion of other causes of encephalopathy. Furthermore, treatment should be tailored to the patient.Learning points:Neurocognitive assessment should be carried out to assess the extent of brain involvement in suspected Hashimoto’s encephalopathy pre- and post- treatment.Treatment of Hashimoto’s encephalopathy should be tailored to the patient.Unifying diagnostic criteria for Hashimoto’s encephalopathy must be established.
eGFR is inversely associated with increasing age and female gender. MDRD derived eGFR fails to completely compensate for age and gender variations and thus different action limits may be required. Small but significant numbers of patients progressed to stages 4 and 5 CKD. Additional clarity in describing "progressive fall in eGFR" in the guidelines would improve identification of the population most at risk.
The Modification of Diet in Renal Disease Study equation-estimated glomerular filtration rate (MDRD-eGFR) as a marker for chronic kidney disease, with a single decision level for both genders and all adult ages, requires that the calculated quantity is independent of gender and age. In a retrospective study of S-Creatinine concentrations from laboratory information systems of hospitals in the UK and Sweden, comprising about 140,000 results in total, it was found that the MDRD-eGFR indeed differs between genders and that it varies with age more than the S-Creatinine concentration does. If the age compensation is deleted from the algorithm, the relative changes in the MDRD-eGFR decrease and become almost the same as those for S-Creatinine concentrations. The difference between the genders could probably be overcome by increasing the "if female factor". We used Pt-Iohexol and S-Creatinine concentrations measured simultaneously to estimate the performance of the MDRD-eGFR in relation to Pt-Iohexol clearance. The Pt-Iohexol varies considerably between patients with the same S-Creatinine concentrations, a difference that is not reflected in the MDRD-eGFR. It is concluded that the mathematical transformation of S-Creatinine concentrations does not add any diagnostic value. On the contrary, an increased measurement uncertainty is unavoidable with the use of factors and exponents. The uncertainty is greater than any difference between age and gender in adjacent age groups. There is no compensation for the individual relation between S-Creatinine and Iohexol clearance, and the equation does not consider the individual body surface area; it is therefore inadvisable to use the MDRD-eGFR values as the basis for administration of drugs excreted by the kidneys.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.